Growth • Larimar Therapeutics
LRMR
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
26,7%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
25,5%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
-11,6%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
18%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!